Duloxetine was approved for the treatment of major depression in 2004. While duloxetine has demonstrated improvement in depression-related symptoms compared to placebo, comparisons of duloxetine to other antidepressant medications have been less successful. A 2012 Cochrane Review did not find greater efficacy of duloxetine compared to SSRIs and newer antidepressants. Additionally, the review found evidence that duloxetine has increased side effects and reduced tolerability compared to other antidepressants. It thus did not recommend duloxetine as a first line treatment for major depressive disorder, given the (then) high cost of duloxetine compared to inexpensive off-patent antidepressants and lack of increased efficacy. do not list duloxetine among the recommended treatment options. A review from the Annals of Internal Medicine lists duloxetine among the first line drug treatments, however, along with citalopram, escitalopram, sertraline, paroxetine, and venlafaxine. Indications and Usage Dosage and Administration Dosage Forms and Strengths Contraindications Warnings and Precautions Adverse Reactions Drug Interactions Use in Specific Populations Drug Abuse and Dependence Overdosage Description Clinical Pharmacology Nonclinical Toxicology Clinical Studies How Supplied/Storage Patient Counseling Information Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Cymbalta or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Cymbalta is not approved for use in pediatric patients. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. Duloxetine maximum dose Viagra 150 mg Doxycycline dose lyme Nov 30, 2012. Product Information - Australia. APO- Duloxetine Enteric Capsules. Page 2. Absorption. In humans, orally administered duloxetine. PI Trade Names and Active Ingredients containing duloxetine. 18 Documents available. Need more information on a product? PI & CMI Trade Names and Active Ingredients containing duloxetine. 21 Documents available. Trade Name, Information Sheet, Active Ingredients. Restricted benefit Duloxetine (Cymbalta) 30 mg and 60 mg capsules can be prescribed on the Pharmaceutical Benefit Scheme (PBS) for people with a major depressive disorder.1 The 30 mg capsule is listed as a month's supply with no repeats. People with renal impairment who require this strength on an ongoing basis will need an authority for any repeats. The Pharmaceutical Benefits Advisory Committee (PBAC) considered duloxetine to be as effective as venlafaxine (Efexor-XR), but with more adverse effects in the first 6 weeks of therapy. In the following 6 weeks the incidence of adverse effects was similar for the two drugs.2 The PBAC had previously accepted as plausible the argument that the discontinuation rate with duloxetine could be reduced by slower dose titration. However, it remained concerned that in trials twice as many people stopped taking duloxetine because of adverse events as stopped taking venlafaxine. 3 Antidepressants are effective in moderate or severe major depressive disorder. There are many different antidepressants available in a number of classes, with similar efficacy but differences in adverse effects. Please contact your doctor or healthcare professional if you have any questions about your medical condition or its treatment. Aspen does not provide medical advice to patients or consumers. For Aspen prescription products you will find information about your medicine in the Consumer Medicine Information section (link to TGA website) available on this website. Duloxetine product information Cymbalta - GuildLink, TGA eBS - Product and Consumer Medicine Information Buy cialis apps/forumBuy propecia online uk cheap Find patient medical information for Duloxetine Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Duloxetine Oral - WebMD - Better information. Better health.. PI - TGA eBS - Product and Consumer Medicine Information. Cymbalta duloxetine hydrochloride capsules - FDA. Prescribing Cymbalta to patients with increased intraocular pressure. See section 4.2 for information on patients with mild or moderate renal dysfunction. PRODUCT INFORMATION Duloxetine REPRESENTATIVE TRADE NAMES Duloxetine – Cymbalta® DRUG CLASS Antidepressant Agents COMPLETE LABELING Product. Duloxetine; Clinical data;. violations at the finished product manufacturing facility. the liver toxicity warning included in the prescribing information.